Silexion Therapeutics (SLXN) was 74% higher in Wednesday's after-hours session, after it disclosed preclinical data demonstrated the synergistic efficacy of its SIL-204 candidate to treat certain form of pancreatic cancer.
The data show that SIL-204 worked well in combination with the primary components of two chemotherapies, 5-fluorouracil and irinotecan, in human cell lines containing pancreatic cancer with KRAS G12D mutations, the most common form of the disease. SIL-204 also showed synergistic activity with gemcitabine, another chemotherapeutic agent, Silexion said.
The company currently is preparing SIL-204 for upcoming clinical trials, with toxicology studies set to begin within a few months and phase 2/3 testing planned for H1 2026, beginning with locally advanced pancreatic cancer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。